Interaction of ochratoxin A with human intestinal Caco-2 cells: possible implication of a multidrug

Valérie Berger1, Anne-Françoise Gabriel, Thérèse Sergent

  • 1Laboratoire de Biochimie cellulaire, Institut des Sciences de la Vie, Université catholique de Louvain, Place Louis Pasteur 1, B-1348, Louvain-la-Neuve, Belgium.

Toxicology Letters
|April 5, 2003
PubMed

Insights

Ochratoxin A (OTA) intestinal absorption is limited by its excretion via the multidrug resistance-associated protein 2 (MRP2) at the apical pole of enterocytes, preventing systemic accumulation.

Area of Science:

  • Toxicology
  • Gastroenterology
  • Cell Biology

Background:

  • Ochratoxin A (OTA) is a nephrotoxic mycotoxin absorbed in the small intestine.
  • OTA's prolonged half-life is attributed to proximal tubule reabsorption and enterohepatic circulation.
  • Understanding intestinal absorption mechanisms is crucial for mitigating OTA toxicity.

Purpose of the Study:

  • To investigate the transport mechanism of Ochratoxin A across the human intestinal epithelium.
  • To identify specific transporters involved in OTA intestinal absorption and intracellular accumulation.
  • To elucidate the role of multidrug resistance-associated proteins (MRPs) in OTA intestinal transport.

Main Methods:

  • Utilized Caco-2 cell culture system as an in vitro model of human intestinal epithelium.
  • Performed cytotoxicity assays to determine OTA's inhibitory concentration (IC50).
  • Assessed transepithelial transport and intracellular accumulation of OTA using bicameral inserts under varying pH conditions and in the presence of transport inhibitors.

Main Results:

  • OTA (0.4 microM) inhibited MTT reduction by 50% in Caco-2 cells.
  • Intestinal absorption was favored under duodenal conditions (AP pH 6.0, BL pH 7.4), enhanced by serum albumin.
  • MRP2 was implicated in OTA apical excretion, limiting transepithelial transport, while P-glycoprotein (P-gp) was also involved.

Conclusions:

  • Intestinal absorption of Ochratoxin A is significantly influenced by pH and the presence of serum albumin.
  • The multidrug resistance-associated protein 2 (MRP2) plays a key role in excreting OTA from enterocytes into the intestinal lumen.
  • MRP2-mediated efflux limits systemic OTA absorption, potentially reducing its nephrotoxic effects.

Related Concept Videos

Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...